Skip to main content

Table 1 Patient characteristics

From: Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients

  No. of patients (%)
  PBC MBC
Variables (N = 9) (N = 57)
Age at biopsy
 Median (range) 56 (31–68) 58 (31–95)
Primary clinical stage
 I 2 (22.2) 22 (38.6)
 II 6 (66.7) 17 (29.8)
 III 1 (11.1) 8 (14)
 IV 0 10 (17.5)
Histological type
 Invasive ductal 9 (100) 53 (93)
 Invasive lobular 0 3 (5.3)
 Mucinous 0 1 (1.8)
Histological grade
 1 6 (66.7) 10 (17.5)
 2 2 (22.2) 27 (47.4)
 3 1 (11.1) 17 (29.8)
 Lobular 0 3 (5.2)
Median percentage of ERα (25%, 75%) 90 (75, 92.5) 85 (70, 90)
Median percentage of PgR (25%, 75%) 10 (5, 45) 30 (5, 60)
HER2
 Positive 0 5 (8.7)
 Negative 9 (100) 52 (91.2)
Presence of ESR1 LBD mutations
 Yes 0 11 (19.3)
 No 9 (100) 46 (80.7)
Number of metastatic organs
 Median (range)   2 (1–5)
Visceral involvement
 Yes   28 (49.1)
 No   29 (50.9)
Metastatic lesions biopsied
 Breast   9 (15.8)
 Skin   19 (33.3)
 Lymph Nodes   14 (24.6)
 Bone   4 (7.0)
 Lung   3 (5.2)
 Liver   4 (7.0)
 Brain   3 (5.2)
 Ovary   1 (1.8)
Number of rounds of prior endocrine therapy
 Median (range)   2 (0–6)
Number of rounds of prior chemotherapy
 Median (range)   0 (0–6)
  1. Abbreviations: ERα estrogen receptor alpha, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2, LBD ligand binding domain, AI aromatase inhibitor, SERM selective estrogen receptor modulator, IBTR ipsilateral breast cancer recurrence